Skip to main content
SpringerLink
Log in

Effects of orally administered glandular kallikrein on urinary kallikrein and prostaglandin excretion, plasma immunoreactive prostanoids and platelet aggregation in essential hypertension

  • Originalien
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

The effects of orally administered glandular kallikrein on urinary kallikrein, aldosterone and prostaglandin E (PGE) excretion, plasma renin activity (PRA), immunoreactive 6-keto PGF1α and thromboxane B2 concentrations and platelet aggregation were studied in 12 patients with essential hypertension (EH). After a 2-week control period, each patient was given orally 450 KU/day of hog glandular kallikrein for 8 weeks. Urinary kallikrein, aldosterone and PGE excretion, and plasma 6-keto PGF1α and thromboxane B2 concentrations were measured by radio-immunoassay. Platelet aggregation was measured by the addition of ADP, collagen or ristocetin with an aggregometer. Urinary kallikrein excretion and plasma 6-keto PGF1α concentration were significantly decreased in patients with EH. There were no significant differences in PRA, urinary aldosterone excretion and plasma thromboxane B2 concentrations between control subjects and patients with EH. There was a significant decrease in blood pressure in patients with EH coinciding with significant increases of urinary kallikrein and PGE excretion and plasma immunoreactive 6-keto PGF1α concentration after administration of glandular kallikrein. There was also a significant inhibition of platelet aggregation induced by collagen in these patients. Thus, a suppression of the kallikrein-kinin-prostaglandin system in patients with EH was found, and a decrease in blood pressure with an increment of urinary kallikrein, PGE excretion, plasma immunoreactive 6-keto PGF1α and inhibition of platelet aggregation in vivo by the administration of glandular kallikrein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

BK:

bradikinin

EH:

essential hypertension

KU:

kallikrein unit

PG:

prostaglandin

PRA:

plasma renin activity

PRP:

platelet rich plasma

TX:

thromboxane

References

  1. Abe K, Seino M, Otsuka Y, Yoshinaga K (1976) Urinary kallikrein excretion and sodium metabolism in human hypertension. In: Pisano JJ, Austen KF (eds) Chemistry and biology of the kallikrein-kinin system in health and disease. U.S. Government Printing Office, Washington. Forgarty Center Proceedings No. 27, 411

    Google Scholar 

  2. Born GV (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:927–929

    Google Scholar 

  3. Carretero OA, Scicli AG (1978) The renal kallikrein-kinin system in human and in experimental hypertension. Klin Wochenschr 56 (suppl 1):113–125

    Google Scholar 

  4. Chen LS, Ito T, Ogawa K, Shikano M, Satake T (1984) Plasma concentrations of 6-keto prostaglandin F1α, thromboxane B2 and platelet aggregation in patients with essential hypertension. Jpn Heart J 25:1001–1009

    Google Scholar 

  5. Elliot AH, Nuzum FR (1934) The urinary excretion of a depressor substance (kallikrein of Frey and Kart) in arterial hypertension. Endocrinology 18:462–474

    Google Scholar 

  6. Fink E, Dietl T, Seifert J, Fritz H (1979) Studies on the biological function of glandular kallikrein. Adv Exp Med Biol 120B, 261–273

    Google Scholar 

  7. FitzGerald GA, Pedersen AK, Patrono C (1983) Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67:1174–1177

    Google Scholar 

  8. Granström E, Samuelsson B (1978) Quantitative measurement of prostaglandins and thromboxanes: General considerations. Frölich (ed) Adv Prostaglandin Thromboxane Res Vol 5. Raven Press, New York, pp 119–210

    Google Scholar 

  9. Grose JH, Lebel M, Gbeassor FM (1980) Diminished urinary prostacyclin metabolites in essential hypertension. Clin Sci (suppl 6):1215–1235

    Google Scholar 

  10. Haber E, Koerner T, Page LB, Kliman B, Purnode A (1967) Application of a radioimmunoassay for angiotensin I to the physiologic measurement of plasma renin activity in normal human subjects. J Clin Endocrinol 29:1349–1355

    Google Scholar 

  11. Jaffe BM (1974) Radioimmunoassay in clinical medicine. Charles C. Thomas, Springfield Ill

    Google Scholar 

  12. Margolius HS, Geller RG, Pisano JJ, Sjoerdsma A (1971) Altered urinary kallikrein excretion in human hypertension. Lancet II 1063–1065

    Google Scholar 

  13. Margolius HS, Geller KF, de Jong W, Pisano JJ, Sjoerdsma A (1972) Urinary kallikrein excretion in hypertension. Circ Res 31 (suppl II):125–131

    Google Scholar 

  14. Morita I, Kanayasu T, Murota S (1984) Kallikrein stimulates prostacyclin in bovine vascular endothelial cells. Biochem Biophys Acta 792:304–309

    Google Scholar 

  15. Nasjletti A, Malik KU (1981) Relationships between the kallikrein-kinin and prostaglandin systems. Life Sci 25:99–109

    Google Scholar 

  16. Overlack A, Stumpe KO, Ressel C, Kolloch R, Zywzok W, Krück F (1980) Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension. Klin Wochenschr 58:37–42

    Google Scholar 

  17. Overlack A, Stumpe KO, Ressel C, Krück F (1979) Low urinary kallikrein excretion and elevated blood pressure normalized by orally applied kallikrein in essential hypertension. Clin Sci 57:263–265

    Google Scholar 

  18. Shimamoto K, Chano J, Margolius HS (1980) The radioimmunoassay of human urinary kallikrein and comparisons with kallikrein activity measurements. J Clin Endocrinol Metab 51:840–848

    Google Scholar 

  19. Smith MC, Dunn MJ (1981) Renal kallikrein, kinins and prostaglandins in hypertension. In: Hypertension, Vol 8: Contemporary Issues in Nephrology. Brenner BM, Stein JH (eds). Churchill Livingstone, New York, pp 168–202

    Google Scholar 

  20. Uehara Y, Ishii T, Ikeda T, Atarashi K, Takeda T, Murao S (1983) Plasma levels of 6-keto-prostaglandin F1α in normotensive subjects and patients with essential hypertension. Prostaglandin, Leukotoriens and Med 11:95–104

    Google Scholar 

  21. Werle E, Korsten H (1938) Der Kallikreingehalt des Herzens, des Speichels und des Blutes bei Gesunden und Kranken. Z Ges Exp Med 103:153–162

    Google Scholar 

  22. Yanaihara T, Okaru Y, Yanaihara N, Kojima A, Sato M, Inoue S, Suzuki K (1981) Intestinal absorption of glandular kallikrein in rabbits. Tan To Sui 2:263–370 (in Japanese)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The 2nd Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan

    K. Ogawa, T. Ito, M. Ban, M. Mochizuki & T. Satake

Authors
  1. K. Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Ban
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Mochizuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Satake
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ogawa, K., Ito, T., Ban, M. et al. Effects of orally administered glandular kallikrein on urinary kallikrein and prostaglandin excretion, plasma immunoreactive prostanoids and platelet aggregation in essential hypertension. Klin Wochenschr 63, 332–336 (1985). https://doi.org/10.1007/BF01731977

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01731977

Key words

Search

Navigation